SCHEMBL994346

SCHEMBL994346

NC1CCCN(Cc2ccccc2)C1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.66
CYP3A4 P08684 3/20 0.66
ALDH1A1 P00352 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP2C19 P33261 1/20 0.66
KDM4E B2RXH2 2/20 0.52
HPGD P15428 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
ACHE P22303 2/20 0.50
BCHE P06276 2/20 0.50
CYP2C9 P11712 2/20 0.50
BACE1 P56817 1/20 0.50
DRD2 P14416 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
KCNH2 Q12809 1/20 0.49
MAOB P27338 1/20 0.49
CCR3 P51677 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227086 1.00 CYP2D6 (0.66) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
SCHEMBL3023682 1.00 CYP2D6 (0.66) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL5266699 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL5266695 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL16333750 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Methane SCHEMBL692994 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL4221752 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL16333749 0.98 CYP2D6 (0.64) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
SCHEMBL556001 0.95 CYP2D6 (0.59) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19
SCHEMBL3459933 0.95 CYP2D6 (0.59) CYP2D6CYP3A4ALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111363732-B Transaminase mutant from aspergillus terreus NIH2624 and application thereof 卡柔恩赛生物技术湖北有限公司 2023-05-23 CN claimed
CN-116042560-A Mutant of recombinant aminotransferase and application thereof 清华大学 2023-05-02 CN claimed
CN-111718250-B Method for preparing R-citronellal 万华化学集团股份有限公司 2022-04-22 CN claimed
CN-110950840-B Preparation method of trelagliptin succinate 江苏天和制药有限公司 2022-03-15 CN claimed
CN-111718250-A Method for preparing R-citronellal 万华化学集团股份有限公司 2020-09-29 CN claimed
CN-111363732-A Transaminase mutant derived from aspergillus terreus NIH2624 and application thereof 重庆迪维斯生物科技有限公司 2020-07-03 CN claimed
CN-110950840-A Preparation method of trelagliptin succinate 江苏天和制药有限公司 2020-04-03 CN claimed
EP-2623593-B1 NOVEL AMINOTRANSFERASE AND GENE ENCODING SAME, AND USE OF THE AMINOTRANSFERASE AND THE GENE KANEKA CORP (JP) 2017-07-12 EP claimed
EP-2684953-B1 MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME KANEKA CORP (JP) 2017-06-28 EP claimed
EP-2623595-B1 NOVEL TRANSAMINASE SHOWING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR UTILIZATION THEREOF KANEKA CORP (JP) 2016-11-02 EP claimed
CN-103534353-A Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same KANEKA CORP 2014-01-22 CN claimed
EP-2684953-A1 MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME Kaneka Corporation (JP) 2014-01-15 EP claimed
US-20140004575-A1 MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME KANEKA CORPORATION (JP) 2014-01-02 US claimed
US-20130210092-A1 Novel Transaminase, Gene Encoding the Same, and Method Using Them KANEKA CORPORATION (JP) 2013-08-15 US claimed
EP-2623593-A1 NOVEL AMINOTRANSFERASE AND GENE ENCODING SAME, AND USE OF THE AMINOTRANSFERASE AND THE GENE Kaneka Corporation (JP) 2013-08-07 EP claimed
EP-2623595-A1 NOVEL TRANSAMINASE SHOWING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR UTILIZATION THEREOF Kaneka Corporation (JP) 2013-08-07 EP claimed
US-20130196389-A1 NOVEL TRANSAMINASE EXHIBITING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR USING THEM KANEKA CORPORATION (JP) 2013-08-01 US claimed
CN-103140580-A Novel aminotransferase, gene encoding the same, and method for using the same KANEKA CORP 2013-06-05 CN claimed
US-20060270847-A1 Process for producing nitrogenous heterocyclic compound TORAY FINE CHEMICALS CO., LTD. (JP) 2006-11-30 US claimed
EP-1640364-A1 PROCESS FOR PRODUCING NITROGENOUS HETEROCYCLIC COMPOUND Toray Fine Chemicals Co., Ltd. (JP) 2006-03-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270847-A1 Process for producing nitrogenous heterocyclic compound HNMT, HRH4, QDPR CYP2D6 745/4885CYP3A4 153/4885ALDH1A1 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.